Study finds menbutone boosts albendazole exposure in calves

A new Frontiers in Veterinary Science study suggests menbutone may modestly increase exposure to albendazole’s active metabolite in calves. Researchers at the University of León gave 12 calves oral albendazole at 7.5 mg/kg either alone or with intramuscular menbutone at 10 mg/kg, using one or two menbutone doses 24 hours apart. Compared with albendazole alone, a single menbutone dose increased albendazole sulfoxide peak plasma concentration by 33.5% and overall exposure by 31.8%, while a second menbutone dose did not add further benefit. The authors frame the finding as a pharmacokinetic interaction that could help optimize use of an established anthelmintic at a time when resistance remains a growing concern. (frontiersin.org)

Why it matters: For veterinary professionals working in cattle practice, the study adds to a small but growing body of evidence that drug disposition can be altered by pairing albendazole with a choleretic agent. Menbutone is used in food-producing species in Europe, and published background literature describes it as stimulating bile, pancreatic, and peptic secretions, a plausible mechanism for improving albendazole dissolution and absorption. Still, this was a 12-animal pharmacokinetic study, not an efficacy trial, so it doesn’t show better parasite clearance, clinical outcomes, or a change that should be translated directly into label use. (frontiersin.org)

What to watch: The next question is whether the higher albendazole sulfoxide exposure seen in calves translates into better field efficacy, practical dosing guidance, or label-relevant evidence in cattle. (frontiersin.org)